S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
NASDAQ:APYX

Apyx Medical (APYX) Stock Price, News & Analysis

$1.32
-0.06 (-4.35%)
(As of 04:20 PM ET)
Today's Range
$1.29
$1.39
50-Day Range
$1.25
$2.71
52-Week Range
$1.21
$7.97
Volume
56,673 shs
Average Volume
147,055 shs
Market Capitalization
$45.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.17

Apyx Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
376.2% Upside
$6.17 Price Target
Short Interest
Healthy
2.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.74) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

158th out of 918 stocks

Surgical & Medical Instruments Industry

26th out of 96 stocks

APYX stock logo

About Apyx Medical Stock (NASDAQ:APYX)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

APYX Stock Price History

APYX Stock News Headlines

Forget NVIDIA, buy this $2 AI stock now…
This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.
Forget NVIDIA, buy this $2 AI stock now…
This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.
Apyx Medical (APYX) Receives a Hold from JMP Securities
Q4 2023 Apyx Medical Corp Earnings Call
Apyx: Q4 Earnings Snapshot
APYX Apr 2024 5.000 put
Craig-Hallum Gives a Buy Rating to Codexis (CDXS)
Apyx Medical Corp
See More Headlines
Receive APYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apyx Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:APYX
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.17
High Stock Price Target
$9.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+346.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,710,000.00
Pretax Margin
-40.65%

Debt

Sales & Book Value

Annual Sales
$52.35 million
Book Value
$0.78 per share

Miscellaneous

Free Float
30,106,000
Market Cap
$47.80 million
Optionable
Optionable
Beta
1.09
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

APYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Apyx Medical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APYX shares.
View APYX analyst ratings
or view top-rated stocks.

What is Apyx Medical's stock price target for 2024?

2 brokers have issued 12 month price targets for Apyx Medical's stock. Their APYX share price targets range from $4.50 to $9.00. On average, they anticipate the company's share price to reach $6.17 in the next year. This suggests a possible upside of 376.2% from the stock's current price.
View analysts price targets for APYX
or view top-rated stocks among Wall Street analysts.

How have APYX shares performed in 2024?

Apyx Medical's stock was trading at $2.62 at the beginning of 2024. Since then, APYX shares have decreased by 50.6% and is now trading at $1.2950.
View the best growth stocks for 2024 here
.

Are investors shorting Apyx Medical?

Apyx Medical saw a drop in short interest in March. As of March 31st, there was short interest totaling 706,700 shares, a drop of 55.0% from the March 15th total of 1,570,000 shares. Based on an average trading volume of 160,300 shares, the days-to-cover ratio is presently 4.4 days. Currently, 2.5% of the company's shares are short sold.
View Apyx Medical's Short Interest
.

When is Apyx Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our APYX earnings forecast
.

How were Apyx Medical's earnings last quarter?

Apyx Medical Co. (NASDAQ:APYX) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.06. The company had revenue of $14.66 million for the quarter, compared to analyst estimates of $14.40 million. Apyx Medical had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 35.75%.

What guidance has Apyx Medical issued on next quarter's earnings?

Apyx Medical updated its FY 2024 earnings guidance on Thursday, March, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $49.7 million-$52.9 million, compared to the consensus revenue estimate of $59.8 million.

What other stocks do shareholders of Apyx Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), ONEOK (OKE), Occidental Petroleum (OXY), Procter & Gamble (PG), STORE Capital (STOR), Wells Fargo & Company (WFC), Boeing (BA), Bank of America (BAC) and Delta Air Lines (DAL).

Who are Apyx Medical's major shareholders?

Apyx Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Silverberg Bernstein Capital Management LLC (1.79%). Insiders that own company stock include Charles D Goodwin II, Matthew C Hill and Todd Hornsby.
View institutional ownership trends
.

How do I buy shares of Apyx Medical?

Shares of APYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APYX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners